Imaging hypoxia and angiogenesis in tumors

Radiologic Clinics of North America

Volumn 43, Issue 1, 2005, Pages 169-187

  Rajendran, Joseph G ^a   Krohn, Kenneth A ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 FLUORO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL; 2 NITROIMIDAZOLE; FLUORINE 18; FLUOROERYTHRONITROIMIDAZOLE; FLUOROETANIDAZOLE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; NITROIMIDAZOLE; RADIOACTIVE IODINE; RADIOISOTOPE; UNCLASSIFIED DRUG; DIAGNOSTIC AGENT; NITROIMIDAZOLE DERIVATIVE;

ANGIOGENESIS; BLOOD SAMPLING; BLOOD VESSEL PERMEABILITY; CANCER DIAGNOSIS; CANCER INVASION; CANCER RADIOTHERAPY; CANCER SCREENING; CARCINOGENESIS; CELL SURVIVAL; CELL VIABILITY; COMPUTER ASSISTED TOMOGRAPHY; CORRELATION ANALYSIS; DISEASE COURSE; DISEASE MARKER; DRUG BLOOD LEVEL; DRUG CLEARANCE; HUMAN; HYPERBARIC OXYGEN; HYPOXIA; IMAGING SYSTEM; ONCOLOGY; OXYGEN SATURATION; PLASMA CLEARANCE; POLAROGRAPHY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEOMICS; RADIOSENSITIVITY; REVIEW; SOMATIC MUTATION; TUMOR CELL; CELL HYPOXIA; METABOLISM; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); SCINTISCANNING; VASCULARIZATION;

CELL HYPOXIA; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; NITROIMIDAZOLES;

EID: 13944273440     PISSN: 00338389     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rcl.2004.08.004     Document Type: Review

References (129)

1. R.L. Wahl Anatomolecular imaging with 2-deoxy-2-[18F]fluoro-D-glucose: bench to outpatient center Mol Imaging Biol 5 2003 49 56
2. H.R. Herschman Molecular imaging: looking at problems, seeing solutions Science 302 2003 605 608
3. J.D. Chapman, J.D. Bradley, J.F. Eary, R. Haubner, S.M. Larson, and J.M. Michalski Molecular (functional) imaging for radiotherapy applications: an RTOG symposium Int J Radiat Oncol Biol Phys 55 2003 294 301
4. J. Rajendran, M. Muzi, L.M. Peterson, A.Z. Diaz, A.M. Spence, and D.S. Schwartz Analyzing the results of [F-18] FMISO PET hypoxia imaging: what is the best way to quantify hypoxia? J Nucl Med 43 2002 102P
5. L. Peters, and M. McKay Predictive assays: will they ever have a role in the clinic? Int J Radiat Oncol Biol Phys 49 2001 501 504
6. D.J. Rowland, J.S. Lewis, and M.J. Welch Molecular imaging: the application of small animal positron emission tomography J Cell Biochem Suppl 39 2002 110 115
7. D. Maclean, J.P. Northrop, H.C. Padgett, and J.C. Walsh Drugs and probes: the symbiotic relationship between pharmaceutical discovery and imaging science Mol Imaging Biol 5 2003 304 311
8. T.L. Collier, R. Lecomte, T.J. McCarthy, S. Meikle, T.J. Ruth, and F. Scopinaro Assessment of cancer-associated biomarkers by positron emission tomography: advances and challenges Dis Markers 18 2002 211 247
9. S.S. Gambhir Molecular imaging of cancer with positron emission tomography Nat Rev Cancer 2 2002 683 693
10. Z.M. Bhujwalla, D. Artemov, E. Aboagye, E. Ackerstaff, R.J. Gillies, and K. Natarajan The physiological environment in cancer vascularization, invasion and metastasis Novartis Found Symp 240 2001 23 38 discussion: 38-45, 152-153
11. R.H. Thomlinson, and L.H. Gray The histological structure of some human lung cancers and the possible implications for radiotherapy Br J Cancer 9 1955 537 549
12. M.I. Kourkourakis, and A. Giotromanolaki Cancer vascularization: implications in radiotherapy? Int J Radiat Oncol Biol Phys 48 2000 545 553S
13. J.G. Rajendran, F. O'Sullivan, L.M. Peterson, D.L. Schwartz, E.U. Conrad, and A.M. Spence Hypoxia and glucose metabolism in malignant tumors: evaluation by FMISO and FDG PET imaging Clin Cancer Res 10 2004 2245 2252
14. A.B. Scandurro, C.W. Weldon, Y.G. Figueroa, J. Alam, and B.S. Beckman Gene microarray analysis reveals a novel hypoxia signal transduction pathway in human hepatocellular carcinoma cells Int J Oncol 19 2001 129 135
15. D.B. Villaret, T. Wang, D. Dillon, J. Xu, D. Sivam, and M.A. Cheever Identification of genes overexpressed in head and neck squamous cell carcinoma using a combination of complementary DNA subtraction and microarray analysis Laryngoscope 110 2000 374 381
16. F. Agani, and G.L. Semenza Mersalyl is a novel inducer of vascular endothelial growth factor gene expression and hypoxia-inducible factor 1 activity Mol Pharmacol 54 1998 749 754
17. M.K. Bae, Y.W. Kwon, M.S. Kim, S.K. Bae, M.H. Bae, and Y.M. Lee Identification of genes differentially expressed by hypoxia in hepatocellular carcinoma cells Biochem Biophys Res Commun 243 1998 158 162
18. G.U. Dachs, and G.M. Tozer Hypoxia modulated gene expression: angiogenesis, metastasis and therapeutic exploitation Eur J Cancer 36 2000 1649 1660
19. R.J. Eisma, J.D. Spiro, and D.L. Kreutzer Vascular endothelial growth factor expression in head and neck squamous cell carcinoma Am J Surg 174 1997 513 517
20. M. Hockel, K. Schlenger, S. Hockel, and P. Vaupel Hypoxic cervical cancers with low apoptotic index are highly aggressive Cancer Res 59 1999 4525 4528
21. K. Guillemin, and M.A. Krasnow The hypoxic response: huffing and HIFing Cell 89 1997 9 12
22. 2 tension Am J Physiol 271 1996 C1172 C1180
23. A.C. Clavo, and R.L. Wahl Effects of hypoxia on the uptake of tritiated thymidine, l-leucine, l-methionine and FDG in cultured cancer cells J Nucl Med 37 1996 502 506
24. P. Burgman, J.A. Odonoghue, J.L. Humm, and C.C. Ling Hypoxia-induced increase in FDG uptake in MCF7 cells J Nucl Med 42 2001 170 175
25. 2 sensing Science 292 2001 464 468
26. L.E. Huang, Z. Arany, D.M. Livingston, and H.F. Bunn Activation of hypoxia-inducible transcription factor depends primarily upon redox-sensitive stabilization of its alpha subunit J Biol Chem 271 1996 32253 32259
27. R. Bos, H. Zhong, C.F. Hanrahan, E.C. Mommers, G.L. Semenza, and H.M. Pinedo Levels of hypoxia-inducible factor-1 alpha during breast carcinogenesis J Natl Cancer Inst 93 2001 309 314
28. H. Zhong, A.M. De Marzo, E. Laughner, M. Lim, D.A. Hilton, and D. Zagzag Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases Cancer Res 59 1999 5830 5835
29. 2 availability in vitro and in vivo Ann Anat 183 2001 243 249
30. H. Yaziji, and A.M. Gown Immunohistochemical analysis of gynecologic tumors Int J Gynecol Pathol 20 2001 64 78
31. J. Folkman Tumor angiogenesis: therapeutic implications N Engl J Med 285 1971 1182 1186
32. P.M. Gullino Angiogenesis and neoplasia N Engl J Med 305 1981 884 885
33. J.D. Hood, and D.A. Cheresh Role of integrins in cell invasion and migration Nat Rev Cancer 2 2002 91 100
34. D.M. McDonald, B.A. Teicher, W. Stetler-Stevenson, S.S. Ng, W.D. Figg, and J. Folkman Report from the Society for Biological Therapy and Vascular Biology Faculty of the NCI Workshop on Angiogenesis Monitoring J Immunother 27 2004 161 175
35. N.G. Costouros, F.E. Diehn, and S.K. Libutti Molecular imaging of tumor angiogenesis J Cell Biochem Suppl 39 2002 72 78
36. W.A. Weber, R. Haubner, E. Vabuliene, B. Kuhnast, H.J. Wester, and M. Schwaiger Tumor angiogenesis targeting using imaging agents Q J Nucl Med 45 2001 179 182
37. M.I. Koukourakis, A. Giatromanolaki, E. Sivridis, and I. Fezoulidis Cancer vascularization: implications in radiotherapy? Int J Radiat Oncol Biol Phys 48 2000 545 553
38. R.K. Jain, N. Safabakhsh, A. Sckell, Y. Chen, P. Jiang, and L. Benjamin Endothelial cell death, angiogenesis, and microvascular function after castration in an androgen-dependent tumor: role of vascular endothelial growth factor Proc Natl Acad Sci U S A 95 1998 10820 10825
39. E.J. Hall Radiobiology for the radiologist 2000 Lippincott Williams & Wilkins Philadelphia
40. B. Marples, O. Greco, M.C. Joiner, and S.D. Scott Molecular approaches to chemo-radiotherapy Eur J Cancer 38 2002 231 239
41. J. Overgaard, and M.R. Horsman Modification of hypoxia-induced radioresistance in tumors by the use of oxygen and sensitizers Semin Radiat Oncol 6 1996 10 21
42. J.F. Fowler Eighth annual Juan del Regato lecture. Chemical modifiers of radiosensitivity-theory and reality: a review Int J Radiat Oncol Biol Phys 11 1985 665 674
43. H. Frommhold, R. Guttenberger, and M. Henke The impact of blood hemoglobin content on the outcome of radiotherapy. The Freiburg experience Strahlenther Onkol 174 Suppl 4 1998 31 34
44. S.M. Evans, and C.J. Koch Prognostic significance of tumor oxygenation in humans Cancer Lett 195 2003 1 16
45. A.C. Koong, N.C. Denko, K.M. Hudson, C. Schindler, L. Swiersz, and C. Koch Candidate genes for the hypoxic tumor phenotype Cancer Res 60 2000 883 887
46. C. Blancher, J.W. Moore, K.L. Talks, S. Houlbrook, and A.L. Harris Relationship of hypoxia-inducible factor (HIF)-1alpha and HIF-2alpha expression to vascular endothelial growth factor induction and hypoxia survival in human breast cancer cell lines Cancer Res 60 2000 7106 7113
47. R.M. Sutherland Tumor hypoxia and gene expression: implications for malignant progression and therapy Acta Oncol 37 1998 567 574
48. O. Amellem, and E.O. Pettersen Cell inactivation and cell cycle inhibition as induced by extreme hypoxia: the possible role of cell cycle arrest as a protection against hypoxia-induced lethal damage Cell Prolif 24 1991 127 141
49. J.E. Moulder, and S. Rockwell Tumor hypoxia: its impact on cancer therapy Cancer Metastasis Rev 5 1987 313 341
50. C. Blancher, and A.L. Harris The molecular basis of the hypoxia response pathway: tumour hypoxia as a therapy target Cancer Metastasis Rev 17 1998 187 194
51. J.M. Brown Exploiting the hypoxic cancer cell: mechanisms and therapeutic strategies Mol Med Today 6 2000 157 162
52. D.J. Lee, M. Moini, J. Giuliano, and W.H. Westra Hypoxic sensitizer and cytotoxin for head and neck cancer Ann Acad Med Singapore 25 1996 397 404
53. A.C. Sartorelli, and W.F. Hodnick Mitomycin C: a prototype bioreductive agent Oncol Res 6 1994 501 508
54. Rajendran J.G., Schwartz D.L., Kinahan P.E., Cheng P., Hummel S.M., Lewellen B., et al. Imaging with F-18 FMISO-PET permits hypoxia directed radiotherapy dose escalation for head and neck cancer. J Nucl Med 2003;44:415, 127P
55. K.S. Chao, W.R. Bosch, S. Mutic, J.S. Lewis, F. Dehdashti, and M.A. Mintun A novel approach to overcome hypoxic tumor resistance: Cu-ATSM-guided intensity-modulated radiation therapy Int J Radiat Oncol Biol Phys 49 2001 1171 1182
56. D. Rischin, L. Peters, R. Hicks, P. Hughes, R. Fisher, and R. Hart Phase I trial of concurrent tirapazamine, cisplatin, and radiotherapy in patients with advanced head and neck cancer J Clin Oncol 19 2001 535 542
57. M.J. Brown The hypoxic cell: a target for selective cancer therapy. Eighteenth Bruce F. Cain memorial award lecture Cancer Res 59 1999 5863 5870
58. M. Hockel, K. Schlenger, C. Knoop, and P. Vaupel Oxygenation of carcinoma of the uterine cervix: evaluation by computerized oxygen tension measurements Cancer Res 51 1991 6098 6102
59. W.J. Koh, K.S. Bergman, J.S. Rasey, L.M. Peterson, M.L. Evans, and M.M. Graham Evaluation of oxygenation status during fractionated radiotherapy in human non small cell lung cancers using [F-18]fluoromisonidazole positron emission tomography Int J Radiat Oncol Biol Phys 33 1995 391 398
60. J.G. Rajendran, D. Wilson, E.U. Conrad, L.M. Peterson, J.D. Bruckner, and J.S. Rasey F-18 FMISO and F-18 FDG PET imaging in soft tissue sarcomas: correlation of hypoxia, metabolism and VEGF expression Eur J Nucl Med 30 2003 695 704
61. Rajendran J.G., Peterson L.M., Schwartz D.L., Scharnhrost J., Conrad E.U., Grierson J.R., et al. F-18 FMISO PET tumor hypoxia imaging: investigating the tumor volume-hypoxia connection. J Nucl Med 2003;44:1340, 1376P
62. M. Adam, E.C. Gabalski, D.A. Bloch, J.W. Ochlert, J.M. Brown, and A.A. Elsaid Tissue oxygen distribution in head and neck cancer patients Head Neck 21 1999 146 153
63. 2 tension measurements Cancer Res 51 1991 6098 6102
64. D.M. Brizel, G.S. Sibley, L.R. Prosnitz, R.L. Scher, and M.W. Dewhirst Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck Int J Radiat Oncol Biol Phys 38 1997 285 289
65. 2) during accelerated radiotherapy of head and neck carcinoma Eur J Cancer 34 1998 856 861
66. M. Nordsmark, M. Overgaard, and J. Overgaard Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck Radiother Oncol 41 1996 31 39
67. Ng P., Peterson L.M., Schwartz D.L., Scharnhrost J., Krohn K.A. Can F-18 fluoromisonidazole PET imaging predict treatment response in head and neck cancer? J Nucl Med 2003;44:416, 128P
68. Muzi M., Spence A.M., Rajendran J.G., Grierson J.R., Krohn K.A. Glioma patients assessed with FMISO and FDG: two tracers provide different Information. J Nucl Med 2003;44:878, 243P
69. P. Valk, C. Mathis, M. Prados, J. Gilbert, and T. Budinger Hypoxia in human gliomas: demonstration by PET with flouorine-18-fluoromisonidazole J Nucl Med 33 1992 2133 2137
70. J. Rajendran, P. Lanell, D.S. Schwartz, M. Muzi, J.D. Scharnhorst, and J.F. Eary [F-18] FMISO PET hypoxia imaging in head and neck cancer: heterogeneity in hypoxia - primary tumor vs lymph nodal metastases J Nucl Med 43 2002 73P
71. H.B. Stone, J.M. Brown, T.L. Phillips, and R.M. Sutherland Oxygen in human tumors: correlations between methods of measurement and response to therapy. Summary of a workshop held November 19-20, 1992, at the National Cancer Institute, Bethesda, Maryland Radiat Res 136 1993 422 434
72. M. Hockel, and P. Vaupel Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects J Natl Cancer Inst 93 2001 266 276
73. J.S. Rasey, J.J. Casciari, P.D. Hofstrand, M. Muzi, M.M. Graham, and L.K. Chin Determining hypoxic fraction in a rat glioma by uptake of radiolabeled fluoromisonidazole Radiat Res 153 2000 84 92
74. P. Vaupel, D.K. Kelleher, and M. Hockel Oxygen status of malignant tumors: pathogenesis of hypoxia and significance for tumor therapy Semin Oncol 28 2001 29 35
75. M. Nozue, I. Lee, and F. Yuan Interlaboratory variation in oxygen tension measurement by eppendorf "histograph" and comparison with hypoxic marker J Surg Oncol 66 1997 30 38
76. E. Lartigau, A.M. Le Ridant, P. Lambin, P. Weeger, L. Martin, and R. Sigal Oxygenation of head and neck tumors Cancer 71 1993 2319 2325
77. D.M. Brizel, G.L. Rosner, J. Harrelson, L.R. Prosnitz, and M.W. Dewhirst Pretreatment oxygenation profiles of human soft tissue sarcomas Int J Radiat Oncol Biol Phys 30 1994 635 642
78. G.V. Martin, J.H. Caldwell, M.M. Graham, J.R. Grierson, K. Kroll, and M.J. Cowan Noninvasive detection of hypoxic myocardium using fluorine-18-fluoromisonidazole and positron emission tomography J Nucl Med 33 1992 2202 2208
79. R.K. Jain Angiogenesis and lymphangiogenesis in tumors: insights from intravital microscopy Cold Spring Harb Symp Quant Biol 67 2002 239 248
80. R.C. Brasch, K.C. Li, J.E. Husband, M.T. Keogan, M. Neeman, and A.R. Padhani In vivo monitoring of tumor angiogenesis with MR imaging Acad Radiol 7 2000 812 823
81. C.N. Chen, Y.M. Cheng, M.T. Lin, F.J. Hsieh, P.H. Lee, and K.J. Chang Association of color Doppler vascularity index and microvessel density with survival in patients with gastric cancer Ann Surg 235 2002 512 518
82. W.F. Cheng, C.N. Lee, J.S. Chu, C.A. Chen, T.M. Chen, and W.Y. Shau Vascularity index as a novel parameter for the in vivo assessment of angiogenesis in patients with cervical carcinoma Cancer 85 1999 651 657
83. W.F. Cheng, T.M. Chen, C.A. Chen, C.C. Wu, K.T. Huang, and C.Y. Hsieh Clinical application of intratumoral blood flow study in patients with endometrial carcinoma Cancer 82 1998 1881 1886
84. J.P. Stevenson, M. Rosen, W. Sun, M. Gallagher, D.G. Haller, and D. Vaughn Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: magnetic resonance imaging evidence for altered tumor blood flow J Clin Oncol 21 2003 4428 4438
85. D.A. Sipkins, D.A. Cheresh, M.R. Kazemi, L.M. Nevin, M.D. Bednarski, and K.C. Li Detection of tumor angiogenesis in vivo by alphaVbeta3-targeted magnetic resonance imaging Nat Med 4 1998 623 626
86. H. Leong-Poi, J.P. Christiansen, A.L. Klibanov, S. Kaul, and J.R. Lindner Noninvasive assessment of angiogenesis by contrast ultrasound imaging with microbubbles targeted to alpha-V integrins J Am Coll Cardiol 41 2003 430 431
87. H. Leong-Poi, J. Christiansen, A.L. Klibanov, S. Kaul, and J.R. Lindner Noninvasive assessment of angiogenesis by ultrasound and microbubbles targeted to alpha(v)-integrins Circulation 107 2003 455 460
88. R. Haubner, H.J. Wester, W.A. Weber, C. Mang, S.I. Ziegler, and S.L. Goodman Noninvasive imaging of alpha(v)beta3 integrin expression using 18F-labeled RGD-containing glycopeptide and positron emission tomography Cancer Res 61 2001 1781 1785
89. R. Haubner, H.J. Wester, F. Burkhart, R. Senekowitsch-Schmidtke, W. Weber, and S.L. Goodman Glycosylated RGD-containing peptides: tracer for tumor targeting and angiogenesis imaging with improved biokinetics J Nucl Med 42 2001 326 336
90. M. Ogawa, K. Hatano, S. Oishi, Y. Kawasumi, N. Fujii, and M. Kawaguchi Direct electrophilic radiofluorination of a cyclic RGD peptide for in vivo alpha(v)beta3 integrin related tumor imaging Nucl Med Biol 30 2003 1 9
91. F.G. Blankenberg, W.C. Eckelman, H.W. Strauss, M.J. Welch, A. Alavi, and C. Anderson Role of radionuclide imaging in trials of antiangiogenic therapy Acad Radiol 7 2000 851 867
92. H. Barthel Endostatin imaging to help understanding of antiangiogenic drugs Lancet Oncol 3 2002 520
93. J.L. Prekeges, J.S. Rasey, Z. Grunbaum, and K.H. Krohn Reduction of fluoromisonidazole, a new imaging agent for hypoxia Biochem Pharmacol 42 1991 2387 2395
94. J.D. Chapman, E.L. Engelhardt, C.C. Stobbe, R.F. Schneider, and G.E. Hanks Measuring hypoxia and predicting tumor radioresistance with nuclear medicine assays Radiother Oncol 46 1998 229 237
95. J.R. Grierson, J.M. Link, C.A. Mathis, J.S. Rasey, and K.A. Krohn Radiosynthesis of fluorine-18 fluoromisonidazole J Nucl Med 30 1989 343 350
96. J.S. Rasey, K. Wui-Jin, M.L. Evans, L.M. Peterson, T.K. Lewellen, and M.M. Graham Quantifying regional hypoxia in human tumors with positron emission tomography of [18F]fluoromisonidazole: a pretherapy study of 37 patients Int J Radiat Oncol Biol Phys 36 1996 417 428
97. J. Rajendran, P. Lanell, D.S. Schwartz, J.D. Scharnhorst, W.J. Koh, and J.F. Eary PET imaging in head and neck cancer with [F-18]FMISO and [F-18] FDG: evaluating different aspects of tumor biology - hypoxia and metabolism Proc Am Assoc Cancer Res 43 2002 758P
98. R.S. Liu, L.S. Chu, S.H. Yen, C.P. Chang, K.L. Chou, and L.C. Wu Detection of anaerobic odontogenic infections by fluorine-18 fluoromisonidazole Eur J Nucl Med 23 1996 1384 1387
99. L. Bentzen, S. Keiding, M.R. Horsman, L. Falborg, S.B. Hansen, and J. Overgaard Feasibility of detecting hypoxia in experimental mouse tumours with 18F-fluorinated tracers and positron emission tomography: a study evaluating [18F]Fluoro-2-deoxy-D-glucose Acta Oncol 39 2000 629 637
100. S.J. Read, T. Hirano, D.F. Abbott, J.I. Sachinidis, H.J. Tochon-Danguy, and J.G. Chan Identifying hypoxic tissue after acute ischemic stroke using PET and 18F-fluoromisonidazole Neurology 51 1998 1617 1621
101. S.H. Yeh, R.S. Liu, L.C. Wu, D.J. Yang, S.H. Yen, and C.W. Chang Fluorine-18 fluoromisonidazole tumour to muscle retention ratio for the detection of hypoxia in nasopharyngeal carcinoma Eur J Nucl Med 23 1996 1378 1383
102. M.M. Graham, L.M. Peterson, J.M. Link, M.L. Evans, J.S. Rasey, and W.J. Koh Fluorine-18-fluoromisonidazole radiation dosimetry in imaging studies J Nucl Med 38 1997 1631 1636
103. J.S. Rasey, W.J. Koh, J.R. Grierson, Z. Grunbaum, and K.A. Krohn Radiolabelled fluoromisonidazole as an imaging agent for tumor hypoxia Int J Radiat Oncol Biol Phys 17 1989 985 991
104. W.J. Koh, J.S. Rasey, M.L. Evans, J.R. Grierson, T.K. Lewellen, and M.M. Graham Imaging of hypoxia in human tumors with [F-18]fluoromisonidazole Int J Radiat Oncol Biol Phys 22 1992 199 212
105. J.J. Casciari, M.M. Graham, and J.S. Rasey A modeling approach for quantifying tumor hypoxia with [F- 18]fluoromisonidazole PET time-activity data Med Phys 22 1995 1127 1139
106. J.D. Chapman, R.F. Schneider, J.L. Urbain, and G.E. Hanks Single-photon emission computed tomography and positron-emission tomography assays for tissue oxygenation Semin Radiat Oncol 11 2001 47 57
107. A. Nunn, K. Linder, and H.W. Strauss Nitroimidazoles and imaging hypoxia Eur J Nucl Med 22 1995 265 280
108. J.E. Biskupiak, and K.A. Krohn Second generation hypoxia imaging agents [editorial; comment] J Nucl Med 34 1993 411 413
109. A.V. Kachur, W.R. Dolbier Jr, S.M. Evans, C.Y. Shiue, G.G. Shiue, and K.A. Skov Synthesis of new hypoxia markers EF1 and [18F]-EF1 Appl Radiat Isot 51 1999 643 650
110. T.J. Tewson Synthesis of [18F]fluoroetanidazole: a potential new tracer for imaging hypoxia Nucl Med Biol 24 1997 755 760
111. L.I. Wiebe, and D. Stypinski Pharmacokinetics of SPECT radiopharmaceuticals for imaging hypoxic tissues Q J Nucl Med 40 1996 270 284
112. B.G. Siim, W.T. Laux, M.D. Rutland, B.N. Palmer, and W.R. Wilson Scintigraphic imaging of the hypoxia marker (99m)technetium-labeled 2,2′-(1,4-diaminobutane)bis(2-methyl-3-butanone) dioxime (99mTc-labeled HL-91; prognox): noninvasive detection of tumor response to the antivascular agent 5,6-dimethylxanthenone-4-acetic acid Cancer Res 60 2000 4582 4588
113. W.L. Rumsey, B. Kuczynski, B. Patel, A. Bauer, R.K. Narra, and S.M. Eaton SPECT imaging of ischemic myocardium using a technetium-99m-nitroimidazole ligand J Nucl Med 36 1995 1445 1450
114. X. Zhang, T. Melo, J.R. Ballinger, and A.M. Rauth Studies of 99mTc-BnAO (HL-91): a non-nitroaromatic compound for hypoxic cell detection Int J Radiat Oncol Biol Phys 42 1998 737 740
115. D. Stypinski, L.I. Wiebe, A.J. McEwan, R.P. Schmidt, Y.K. Tam, and J.R. Mercer Clinical pharmacokinetics of 123I-IAZA in healthy volunteers Nucl Med Commun 20 1999 559 567
116. M.E. Shelton, M.A. Green, C.J. Mathias, M.J. Welch, and S.R. Bergmann Assessment of regional myocardial and renal blood flow with copper-PTSM and positron emission tomography Circulation 82 1990 990 997
117. J.S. Lewis, D.W. McCarthy, T.J. McCarthy, Y. Fujibayashi, and M.J. Welch Evaluation of Cu-64-ATSM in vitro and in vivo in a hypoxic model J Nucl Med 40 1999 177 183
118. F. Dehdashti, M.A. Mintun, J.S. Lewis, J. Bradley, R. Govindan, and R. Laforest In vivo assessment of tumor hypoxia in lung cancer with 60Cu-ATSM Eur J Nucl Med Mol Imaging 30 2003 844 850
119. Y. Fujibayashi, H. Taniuchi, Y. Yonekura, H. Ohtani, J. Konishi, and A. Yokoyama Copper-62-ATSM: a new hypoxia imaging agent with high membrane permeability and low redox potential J Nucl Med 38 1997 1155 1160
120. J.R. Ballinger Imaging hypoxia in tumors Semin Nucl Med 31 2001 321 329
121. E.C. Gabalski, M. Adam, H. Pinto, J.M. Brown, D.A. Bloch, and D.J. Terris Pretreatment and midtreatment measurement of oxygen tension levels in head and neck cancers Laryngoscope 108 1998 1856 1860
122. B.M. Klabbers, A.A. Lammertsma, and B.J. Slotman The value of positron emission tomography for monitoring response to radiotherapy in head and neck cancer Mol Imaging Biol 5 2003 257 270
123. M. Alber, F. Paulsen, S.M. Eschmann, and H.J. Machulla On biologically conformal boost dose optimization Phys Med Biol 48 2003 N31 N35
124. C.C. Ling, J. Humm, S. Larson, H. Amols, Z. Fuks, and S. Leibel Towards multidimensional radiotherapy (MD-CRT): biological imaging and biological conformality Int J Radiat Oncol Biol Phys 47 2000 551 560
125. W.A. Tome, and J.F. Fowler Selective boosting of tumor subvolumes Int J Radiat Oncol Biol Phys 48 2000 593 599
126. L.J. Peters Targeting hypoxia in head and neck cancer Acta Oncol 40 2001 937 940
127. B. Solomon, G. McArthur, C. Cullinane, J. Zalcberg, and R. Hicks Applications of positron emission tomography in the development of molecular targeted cancer therapeutics BioDrugs 17 2003 339 354
128. M.T. Klimas Positron emission tomography and drug discovery: contributions to the understanding of pharmacokinetics, mechanism of action and disease state characterization Mol Imaging Biol 4 2002 311 337
129. L.A. Hammond, L. Denis, U. Salman, P. Jerabek, C.R. Thomas Jr, and J.G. Kuhn Positron emission tomography (PET): expanding the horizons of oncology drug development Invest New Drugs 21 2003 309 340